tbuckley/cabot-search huggingface dataset:
Adverse childhood experiences: a meta‐analysis of prevalence and moderators among half a million adults in 206 studies
Authors: Sheri Madigan, Audrey‐Ann Deneault, Nicole Racine, Julianna Park, Raela Thiemann, Jenney Zhu, Gina Dimitropoulos, Tyler Williamson, Pasco Fearon, Jude Mary Cénat, Sheila McDonald, Chloe Devereux, Ross D. Neville
Journal: World Psychiatry (2023)

Exposure to adverse childhood experiences (ACEs), including maltreatment and family dysfunction, is a major contributor to the global burden of disease and disability. With a large body of international literature on ACEs having emerged over the past 25 years, it is timely to now synthetize the available evidence to estimate the global prevalence of ACEs and, through a series of moderator analyses, determine which populations are at higher risk. We searched studies published between January 1, 1998 and August 5, 2021 in Medline, PsycINFO and Embase. Study inclusion criteria were using the 8‐ or 10‐item ACE Questionnaire (±2 items), reporting the prevalence of ACEs in population samples of adults, and being published in English. The review protocol was registered with PROSPERO (CRD42022348429). In total, 206 studies (208 sample estimates) from 22 countries, with 546,458 adult participants, were included. The pooled prevalence of the five levels of ACEs was: 39.9% (95% CI: 29.8‐49.2) for no ACE; 22.4% (95% CI: 14.1‐30.6) for one ACE; 13.0% (95% CI: 6.5‐19.8) for two ACEs; 8.7% (95% CI: 3.4‐14.5) for three ACEs, and 16.1% (95% CI: 8.9‐23.5) for four or more ACEs. In subsequent moderation analyses, there was strong evidence that the prevalence of 4+ ACEs was higher in populations with a history of a mental health condition (47.5%; 95% CI: 34.4‐60.7) and with substance abuse or addiction (55.2%; 95% CI: 45.5‐64.8), as well as in individuals from low‐income households (40.5%; 95% CI: 32.9‐48.4) and unhoused individuals (59.7%; 95% CI: 56.8‐62.4). There was also good evidence that the prevalence of 4+ ACEs was larger in minoritized racial/ethnic groups, particularly when comparing study estimates in populations identifying as Indigenous/Native American (40.8%; 95% CI: 23.1‐59.8) to those identifying as White (12.1%; 95% CI: 10.2‐14.2) and Asian (5.6%; 95% CI: 2.4‐10.2). Thus, ACEs are common in the general population, but there are disparities in their prevalence. They are among the principal antecedent threats to individual well‐being and, as such, constitute a pressing social issue globally. Both prevention strategies and downstream interventions are needed to reduce the prevalence and mitigate the severity of the effects of ACEs and thereby reduce their deleterious health consequences on future generations.
The lived experience of depression: a bottom‐up review co‐written by experts by experience and academics
Authors: Paolo Fusar‐Poli, Andrés Estradé, Giovanni Stanghellini, Cecilia Maria Esposito, René Rosfort, Milena Mancini, Peter Norman, Julieann Cullen, Miracle Adesina, Gema Benavides Jimenez, Caroline da Cunha Lewin, Esenam A. Drah, Marc Julien, Muskan Lamba, Edwin M. Mutura, Benny Prawira, Agus Sugianto, Jaleta Teressa, Lawrence A. White, Stefano Damiani, Candida Vasconcelos, Ilaria Bonoldi, Pierluigi Politi, Eduard Vieta, Jennifer Radden, Thomas Fuchs, Matthew Ratcliffe, Mario Maj
Journal: World Psychiatry (2023)

We provide here the first bottom-up review of the lived experience of depression, co-written by experts by experience and academics. First-person accounts within and outside the medical field were screened and discussed in collaborative workshops involving numerous individuals with lived experience of depression, family members and carers, representing a global network of organizations. The material was enriched by phenomenologically informed perspectives and shared with all collaborators in a cloud-based system. The subjective world of depression was characterized by an altered experience of emotions and body (feeling overwhelmed by negative emotions, unable to experience positive emotions, stuck in a heavy aching body drained of energy, detached from the mind, the body and the world); an altered experience of the self (losing sense of purpose and existential hope, mismatch between the past and the depressed self, feeling painfully incarcerated, losing control over one's thoughts, losing the capacity to act on the world; feeling numb, empty, non-existent, dead, and dreaming of death as a possible escape route); and an altered experience of time (experiencing an alteration of vital biorhythms, an overwhelming past, a stagnation of the present, and the impossibility of the future). The experience of depression in the social and cultural context was characterized by altered interpersonal experiences (struggling with communication, feeling loneliness and estrangement, perceiving stigma and stereotypes), and varied across different cultures, ethnic or racial minorities, and genders. The subjective perception of recovery varied (feeling contrasting attitudes towards recovery, recognizing recovery as a journey, recognizing one's vulnerability and the need for professional help), as did the experience of receiving pharmacotherapy, psychotherapy, and social as well as physical health interventions. These findings can inform clinical practice, research and education. This journey in the lived experience of depression can also help us to understand the nature of our own emotions and feelings, what is to believe in something, what is to hope, and what is to be a living human being.
Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells
Authors: Feng Shan, Anthony R. Cillo, Carly Cardello, Daniel Y. Yuan, Sheryl R. Kunning, Jian Cui, Caleb Lampenfeld, Asia M. Williams, Alexandra P. McDonough, Arjun Pennathur, James D. Luketich, John M. Kirkwood, Robert L. Ferris, Tullia C. Bruno, Creg J. Workman, Panayiotis V. Benos, Dario A. A. Vignali
Journal: Science Immunology (2023)

Human regulatory T cells (T
Lung tumor–infiltrating T<sub>reg</sub>have divergent transcriptional profiles and function linked to checkpoint blockade response
Authors: Arbor G. Dykema, Jiajia Zhang, Laurene S. Cheung, Sydney Connor, Boyang Zhang, Zhen Zeng, Christopher M. Cherry, Taibo Li, Justina X. Caushi, Marni Nishimoto, Andrew J. Munoz, Zhicheng Ji, Wenpin Hou, Wentao Zhan, Dipika Singh, Tianbei Zhang, Rufiaat Rashid, Marisa Mitchell-Flack, Sadhana Bom, Ada Tam, Nick Ionta, Thet H. K. Aye, Yi Wang, Camille A. Sawosik, Lauren E. Tirado, Luke M. Tomasovic, Derek VanDyke, Jamie B. Spangler, Valsamo Anagnostou, Stephen Yang, Jonathan Spicer, Roni Rayes, Janis Taube, Julie R. Brahmer, Patrick M. Forde, Srinivasan Yegnasubramanian, Hongkai Ji, Drew M. Pardoll, Kellie N. Smith
Journal: Science Immunology (2023)

Regulatory T cells (T reg ) are conventionally viewed as suppressors of endogenous and therapy-induced antitumor immunity; however, their role in modulating responses to immune checkpoint blockade (ICB) is unclear. In this study, we integrated single-cell RNA-seq/T cell receptor sequencing (TCRseq) of &gt;73,000 tumor-infiltrating T reg (TIL-T reg ) from anti–PD-1–treated and treatment-naive non–small cell lung cancers (NSCLC) with single-cell analysis of tumor-associated antigen (TAA)–specific T reg derived from a murine tumor model. We identified 10 subsets of human TIL-T reg , most of which have high concordance with murine TIL-T reg subsets. Only one subset selectively expresses high levels of TNFRSF4 (OX40) and TNFRSF18 (GITR), whose engangement by cognate ligand mediated proliferative programs and NF-κB activation, as well as multiple genes involved in T reg suppression, including LAG3 . Functionally, the OX40 hi GITR hi subset is the most highly suppressive ex vivo, and its higher representation among total TIL-T reg correlated with resistance to PD-1 blockade. Unexpectedly, in the murine tumor model, we found that virtually all TIL-T reg –expressing T cell receptors that are specific for TAA fully develop a distinct T H 1-like signature over a 2-week period after entry into the tumor, down-regulating FoxP3 and up-regulating expression of TBX21 ( Tbet) , IFNG , and certain proinflammatory granzymes. Transfer learning of a gene score from the murine TAA-specific T H 1-like T reg subset to the human single-cell dataset revealed a highly analogous subcluster that was enriched in anti–PD-1–responding tumors. These findings demonstrate that TIL-T reg partition into multiple distinct transcriptionally defined subsets with potentially opposing effects on ICB-induced antitumor immunity and suggest that TAA-specific TIL-T reg may positively contribute to antitumor responses.
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial
Authors: Dennis I. Narcisse, Hwasoon Kim, Lisa M. Wruck, Amanda L. Stebbins, Daniel Muñoz, Sunil Kripalani, Mark B. Effron, Kamal Gupta, R. David Anderson, Sandeep K. Jain, Saket Girotra, Jeff Whittle, Catherine P. Benziger, Peter Farrehi, Li Zhou, Tamar S. Polonsky, Faraz S. Ahmad, Matthew T. Roe, Russell L. Rothman, Robert A. Harrington, Adrian F. Hernandez, W. Schuyler Jones
Journal: Diabetes Care (2023)

Patients with diabetes mellitus (DM) and concomitant atherosclerotic cardiovascular disease (ASCVD) must be on the most effective dose of aspirin to mitigate risk of future adverse cardiovascular events.ADAPTABLE, an open-label, pragmatic study, randomized patients with stable, chronic ASCVD to 81 mg or 325 mg of daily aspirin. The effects of aspirin dosing was assessed on the primary effectiveness outcome, a composite of all-cause death, hospitalization for myocardial infarction, or hospitalization for stroke, and the primary safety outcome of hospitalization for major bleeding. In this prespecified analysis, we used Cox proportional hazards models to compare aspirin dosing in patients with and without DM for the primary effectiveness and safety outcome.Of 15,076 patients, 5,676 (39%) had DM of whom 2,820 (49.7%) were assigned to 81 mg aspirin and 2,856 (50.3%) to 325 mg aspirin. Patients with versus without DM had higher rates of the composite cardiovascular outcome (9.6% vs. 5.9%; P < 0.001) and bleeding events (0.78% vs. 0.50%; P < 0.001). When comparing 81 mg vs. 325 mg of aspirin, patients with DM had no difference in the primary effectiveness outcome (9.3% vs. 10.0%; hazard ratio [HR] 0.98 [95% CI 0.83-1.16]; P = 0.265) or safety outcome (0.87% vs. 0.69%; subdistribution HR 1.25 [95% CI 0.72-2.16]; P = 0.772).This study confirms the inherently higher risk of patients with DM irrespective of aspirin dosing. Our findings suggest that a higher dose of aspirin yields no added clinical benefit, even in a more vulnerable population.
Glioma genetic profiles associated with electrophysiologic hyperexcitability
Authors: Steven Tobochnik, Maria Kristina C Dorotan, Hia S Ghosh, Emily Lapinskas, Jayne Vogelzang, David A Reardon, Keith L Ligon, Wenya Linda Bi, Stelios M Smirnakis, Jong Woo Lee
Journal: Neuro-Oncology (2023)

Distinct genetic alterations determine glioma aggressiveness, however, the diversity of somatic mutations contributing to peritumoral hyperexcitability and seizures over the course of the disease is uncertain. This study aimed to identify tumor somatic mutation profiles associated with clinically significant hyperexcitability.
When I use a word . . . The ambiguity of “work” in the ICMJE recommendations on publishing in medical journals
Authors: Jeffrey K Aronson
Journal: BMJ (2023)

The word "work" has many different meanings. Among these are (a) the scholarly activity that researchers undertake and (b) the publication in which they describe the results of that activity. Both can be described using the word "work." In the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals published by the International Committee of Medical Journal Editors (ICMJE), the word "work" has each of these meanings in different places; in several cases the intended meaning is ambiguous. Because of these ambiguities, authors can have difficulties in interpreting the ICMJE9s recommendations.
Menstrual health must be prioritised in global policies
Authors: Jennifer S Martin, Joan Masinde, Antonia Cañizares, Sidra Irfan, Arush Lal
Journal: BMJ (2023)

Menstrual health is the gateway to promoting sexual and reproductive health rights, building body autonomy and self-efficacy, elevating women's leadership, and improving health literacy.However, its full potential has not been recognised by global leaders, and menstrual health has been omitted from key global conventions. Accelerating progress on the sustainable development goalsMainstreaming menstrual health across global policies and treaties could reinforce the need for
Author Correction: An ATP-sensitive phosphoketolase regulates carbon fixation in cyanobacteria
Authors: Kuan-Jen Lu, Chiung-Wen Chang, Chun-Hsiung Wang, Frederic Y-H Chen, Irene Y. Huang, Pin-Hsuan Huang, Cheng-Han Yang, Hsiang-Yi Wu, Wen-Jin Wu, Kai-Cheng Hsu, Meng-Chiao Ho, Ming-Daw Tsai, James C. Liao
Journal: Nature Metabolism (2023)
Complete response to immunotherapy in a patient with high-risk stage III colorectal cancer after ctDNA-guided detection of early adjuvant treatment failure
Authors: Nicholas Lucchesi, Jenna M Ally, Matthew J Reilley
Journal: Journal for ImmunoTherapy of Cancer (2023)

The standard of care for stage III colorectal cancer (CRC) is curative resection with adjuvant chemotherapy (ACT). There is a high risk of recurrence particularly for high-risk patients with stage III disease, making close disease monitoring vital. Circulating tumor DNA (ctDNA) is now established as an effective method of early detection of disease relapse as well as postoperative risk stratification. However there remains a lack of established protocol for using ctDNA to assess response to ACT and in using that data to alter therapy in real time. A case is described of a patient with high-risk stage III CRC in whom failure of ACT was detected early and therapy was quickly changed based on rising ctDNA levels. The described patient had complete radiologic and clinical response to checkpoint inhibitor immunotherapy and remains free of disease after 18 months. This case demonstrates a promising example of how ctDNA can be used to both assess effectiveness of ongoing therapy and drive real-time change in treatment while sparing unnecessary chemotherapy toxicities.
On-Demand Diaphragm Pacing in Invasively Mechanically Ventilated Patients with Severe Hypoxemia in the ICU: New Hope in Acute Respiratory Distress Syndrome?
Authors: Jens Spiesshoefer, Michael Dreher
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"On-Demand Diaphragm Pacing in Invasively Mechanically Ventilated Patients with Severe Hypoxemia in the Intensive Care Unit: New Hope in ARDS?." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Protease-armed, Pathogenic Extracellular Vesicles Link Smoking and Chronic Obstructive Pulmonary Disease
Authors: Matthew C. Madison, Camilla Margaroli, Kristopher R. Genschmer, Derek W. Russell, James M. Wells, Ezgi Sari, Yixel M. Soto-Vazquez, Yuan-Yuan Guo, Kyle T. Mincham, Robert J. Snelgrove, Amit Gaggar, James E. Blalock
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Mounting evidence demonstrates a role for extracellular vesicles (EVs) in driving lung disorders, such as chronic obstructive pulmonary disease (COPD). Although cigarette smoke (CS) is the primary risk factor for COPD, a link between CS and the EVs that could lead to COPD is unknown.
Wood structure-inspired injectable lignin-based nanogels as blood-vessel-embolic sustained drug-releasing stent for interventional therapies on liver cancer
Authors: Ze Zheng, Hongsen Zhang, Kun Qian, Ling Li, Dingwen Shi, Ran Zhang, Ling Li, Hongbo Yu, Chuansheng Zheng, Shangxian Xie, Yanbing Zhao, Xiangliang Yang
Journal: Biomaterials (2023)
Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study
Authors: Eric Yuk Fai Wan, Anna Hoi Ying Mok, Vincent Ka Chun Yan, Cheyenne I. Ying Chan, Boyuan Wang, Francisco Tsz Tsun Lai, Celine Sze Ling Chui, Xue Li, Carlos King Ho Wong, Kai Hang Yiu, Hung Fat Tse, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan
Journal: Cell Reports Medicine (2023)

It is unknown if vaccination affects the risk of post-COVID-19 cardiovascular diseases (CVDs). Therefore, this retrospective cohort study examines the short-term and long-term risks of post-infection CVD among COVID-19 patients with different vaccination status utilizing data from electronic health databases in Hong Kong. Cox proportional hazards regression adjusted with inverse probability of treatment weighting is used to evaluate the risks of incident CVD (coronary heart disease, stroke, heart failure) and all-cause mortality in COVID-19 patients. Compared with unvaccinated patients, vaccinated patients have a lower risk of CVD and all-cause mortality, and the lowest risk is observed in those who completed three doses of vaccine. Similar patterns in the subgroups of different vaccine platforms, age, gender, Charlson comorbidity index, and disease severity are observed. These findings highlight a positive dose-response relationship between overall CVD risk reduction and the number of vaccine doses received.
The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring
Authors: Syeda Maheen Batool, Anudeep Yekula, Prerna Khanna, Tiffaney Hsia, Austin S. Gamblin, Emil Ekanayake, Ana K. Escobedo, Dong Gil You, Cesar M. Castro, Hyungsoon Im, Tugba Kilic, Michelle Andrea Garlin, Johan Skog, Daniela M. Dinulescu, Jonathan Dudley, Nishant Agrawal, Jordan Cheng, Fereidoun Abtin, Denise R. Aberle, David Chia, David Elashoff, Tristan Grognan, Kostyantyn Krysan, Scott S. Oh, Charles Strom, Michael Tu, Fang Wei, Rena R. Xian, Steven J. Skates, David Y. Zhang, Thi Trinh, Mark Watson, Rebecca Aft, Siddarth Rawal, Ashutosh Agarwal, Susan B. Kesmodel, Changhuei Yang, Cheng Shen, Fred H. Hochberg, David T.W. Wong, Abhijit A. Patel, Nickolas Papadopoulos, Chetan Bettegowda, Richard J. Cote, Sudhir Srivastava, Hakho Lee, Bob S. Carter, Leonora Balaj
Journal: Cell Reports Medicine (2023)

The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.
Parkinson’s disease-linked parkin mutation disrupts recycling of synaptic vesicles in human dopaminergic neurons
Authors: Pingping Song, Wesley Peng, Veronique Sauve, Rayan Fakih, Zhong Xie, Daniel Ysselstein, Talia Krainc, Yvette C. Wong, Niccolò E. Mencacci, Jeffrey N. Savas, D. James Surmeier, Kalle Gehring, Dimitri Krainc
Journal: Neuron (2023)
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
Authors: Paul J. Hengeveld, P. Martijn Kolijn, Jeroen A.A. Demmers, Wouter Doff, Julie M.N. Dubois, Melissa Rijken, Jorn L.J.C. Assmann, Lina van der Straten, Henk Jan Boiten, Kirsten J. Gussinklo, Peter J.M. Valk, Laura M. Faber, Peter E. Westerweel, Arnon P. Kater, Mark-David Levin, Anton W. Langerak
Journal: HemaSphere (2023)

It remains challenging in chronic lymphocytic leukemia (CLL) to distinguish between patients with favorable and unfavorable time-to-first treatment (TTFT). Additionally, the downstream protein correlates of well-known molecular features of CLL are not always clear. To address this, we selected 40 CLL patients with TTFT ≤24 months and compared their B cell intracellular protein expression with 40 age- and sex-matched CLL patients with TTFT &gt;24 months using mass spectrometry. In total, 3268 proteins were quantified in the cohort. Immunoglobulin heavy-chain variable (IGHV) mutational status and trisomy 12 were most impactful on the CLL proteome. Comparing cases to controls, 5 proteins were significantly upregulated, whereas 3 proteins were significantly downregulated. Of these, only THEMIS2, a signaling protein acting downstream of the B cell receptor, was significantly associated with TTFT, independently of IGHV and TP53 mutational status (hazard ratio, 2.49 [95% confidence interval, 1.62-3.84]; P &lt; 0.001). This association was validated on the mRNA and protein level by quantitative polymerase chain reaction and ELISA, respectively. Analysis of 2 independently generated RNA sequencing and mass spectrometry datasets confirmed the association between THEMIS2 expression and clinical outcome. In conclusion, we present a comprehensive characterization of the proteome of untreated CLL and identify THEMIS2 expression as a putative biomarker of TTFT.
An ‘embedded brain’ approach to understanding antisocial behaviour
Authors: Essi Viding, Eamon McCrory, Arielle Baskin-Sommers, Stephane De Brito, Paul Frick
Journal: Trends in Cognitive Sciences (2023)

Antisocial behaviour (ASB) incurs substantial costs to the individual and society. Cognitive neuroscience has the potential to shed light on developmental risk for ASB, but it cannot achieve this potential in an 'essentialist' framework that focuses on the brain and cognition isolated from the environment. Here, we present the case for studying the social transactional and iterative unfolding of brain and cognitive development in a relational context. This approach, which we call the study of the 'embedded brain', is needed to fully understand how risk for ASB arises during development. Concentrated efforts are required to develop and unify methods to achieve this approach and reap the benefits for improved prevention and intervention of ASB.
Dual-driven nanomotors enable tumor penetration and hypoxia alleviation for calcium overload-photo-immunotherapy against colorectal cancer
Authors: Jiaxue Wu, Shixiong Yi, Yingui Cao, Menghang Zu, Baoyi Li, Wenjing Yang, Mohammad-Ali Shahbazi, Ying Wan, Rui L. Reis, Subhas C. Kundu, Xiaoxiao Shi, Bo Xiao
Journal: Biomaterials (2023)
Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study)
Authors: Wei Jiang, Selmir Avdic, Koon H. Lee, Janine Street, Gloria Castellano-González, Renee Simms, Leighton E. Clancy, Richard Blennerhassett, Ellis Patrick, Adam S. Chan, Helen M. McGuire, Nadav Myers, Brian S. Gloss, Melissa Gabriel, Caroline M. Bateman, Ken Micklethwaite, David J. Gottlieb, Emily Blyth
Journal: Leukemia (2023)
A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML
Authors: Wenxin Du, Zhimei Xia, Zebin Luo, Yichang Chen, Shaowei Bing, Wei Wang, Xingya Zhang, Zhan Zhou, Jingying Zhang, Ji Cao, Bo Yang, Qiaojun He, Xuejing Shao, Xiaojun Xu, Meidan Ying
Journal: Leukemia (2023)